KIT and gastrointestinal stromal tumor: The occurrence of secondary KIT mutations in more than 90% of GIST patients led to the approval of multi type II TKIs targeting KIT and PDGFRA [1], including sunitinib (SU) in 2006 and regorafenib (REG) in 2013 [9,10].